Merz Therapeutics acquires INBRIJA and FAMPYRA from Acorda Therapeutics to bolster neurological portfolio

In a strategic move enhancing its presence in the neurology sector, Merz Therapeutics has successfully completed the acquisition of INBRIJA (levodopa inhalation powder) and FAMPYRA (fampridine), along with related assets, from Acorda Therapeutics, Inc. This transaction, valued at USD 185 million in cash, was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code, marking a significant expansion for Merz into the Parkinson’s disease and multiple sclerosis (MS) domains.

The acquisition is pivotal for Merz Therapeutics as it not only diversifies its product portfolio but also promises an immediate increase in topline revenue. Stefan König, CEO of Merz Therapeutics, underscored the acquisition’s alignment with the company’s ‘Pivot for Growth’ strategy, aiming to enhance the current portfolio and achieve critical scale globally. “The addition of INBRIJA and FAMPYRA expands our specialty in neurology, strengthening our position in Parkinson’s disease management and propelling us into the MS segment,” König noted.

INBRIJA represents a significant advancement in Parkinson’s disease treatment, offering an on-demand, inhalable form of levodopa for managing “OFF” episodes experienced by patients. This novel delivery method, facilitated by ARCUS® technology, provides rapid symptom relief not consistently achievable with oral medications.

Meanwhile, FAMPYRA, known as AMPYRA in the U.S., stands as the first medication approved for improving walking in MS patients, evidenced by increased walking capabilities in clinical settings.

With projections indicating that over 75% of INBRIJA’s and FAMPYRA’s global revenues will stem from the U.S. market in the next decade, Merz anticipates substantial growth. This acquisition is expected to lead to a more than 50% increase in the U.S. workforce, reflecting the company’s commitment to expanding its operational capabilities and clinical development of new and existing assets.

The integration of these treatments into Merz Therapeutics’ portfolio not only complements its existing products but also extends the company’s reach in providing critical support to patients with neurological disorders. Stefan Albrecht, Chief Scientific and Medical Officer, highlighted the strategic benefits: “Expanding with INBRIJA and FAMPYRA allows us to leverage our neurology expertise globally, offering enhanced support to patients and physicians alike.”